Company Profiles

driven by the PitchBook Platform

Arsanis

Description

Developer of monoclonal antibodies (mAbs) designed to prevent and treat serious infectious diseases. The company's monoclonal antibodies (mAbs) has transformed the treatment of a wide range of diseases from cancer to immune system disorders, it can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes, enabling physicians to redefining the practice of medicine for serious infections.

2010

Founded

PRIVATE

Status

11-50

Employees

Series D

Latest Deal Type

$45.5M

Latest Deal Amount

$90.5M

Total Amount Raised

Description

Developer of monoclonal antibodies (mAbs) designed to prevent and treat serious infectious diseases. The company's monoclonal antibodies (mAbs) has transformed the treatment of a wide range of diseases from cancer to immune system disorders, it can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes, enabling physicians to redefining the practice of medicine for serious infections.

Website:

www.arsanis.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

890 Winter Street Suite 230 Waltham, MA 02451United States
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Arsanis's full profile, request a free trial.

Arsanis Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Arsanis Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Arsanis Investors (9)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Alexandria Real Estate EquitiesReal EstateMinority000 0000000 0000
Anna Maria And Stephen Kellen FoundationOtherMinority000 0000000 0000
Bill & Melinda Gates FoundationNot-For-Profit Venture CapitalMinority000 0000000 0000
EMBL VenturesVenture CapitalMinority000 0000000 0000
GVCorporate Venture CapitalMinority000 0000000 0000
Alexandria Real Estate Equities Real Estate
Anna Maria And Stephen Kellen Foundation Other
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital
EMBL Ventures Venture Capital
GV Corporate Venture Capital

Arsanis Executive Team (6)

NameTitleBoard
Seat
Contact
Info
Eszter Nagy Ph.DCo-Founder, Managing Director, Board Member & Chief Scientific Officer
Rene RussoPresident, Board Member & Chief Executive Officer
Michael GrayChief Financial Officer & Chief Business Officer
David Mantus Ph.DChief Development Officer
Steven Luperchio Ph.DDirector of Clinical and Medical Research
Eszter Nagy Ph.D Co-Founder, Managing Director, Board Member & Chief Scientific Officer
Rene Russo President, Board Member & Chief Executive Officer
Michael Gray Chief Financial Officer & Chief Business Officer
David Mantus Ph.D Chief Development Officer
Steven Luperchio Ph.D Director of Clinical and Medical Research

Arsanis Board Members (10)

NameRepresentingRoleSinceContact
Info
Amy Schulman JDPolaris PartnersVenture Partner000 0000
Carl Gordon Ph.DOrbiMedFounding Partner & Co-Head of Global Private Equity000 0000
Claudio Nessi Ph.DNeoMed ManagementManaging Partner000 0000
Daniel BurgessSV Health InvestorsVenture Partner000 0000
Eszter Nagy Ph.DArsanisCo-Founder, Managing Director, Board Member & Chief Scientific Officer000 0000
Amy Schulman JD Venture Partner Polaris Partners
Carl Gordon Ph.D Founding Partner & Co-Head of Global Private Equity OrbiMed
Claudio Nessi Ph.D Managing Partner NeoMed Management
Daniel Burgess Venture Partner SV Health Investors
Eszter Nagy Ph.D Co-Founder, Managing Director, Board Member & Chief Scientific Officer Arsanis
Request full access to PitchBook